Pevonedistat通过抑制NFκB通路靶向骨髓增殖性肿瘤细胞
该研究探讨Pevonedistat通过抑制NFκB通路靶向骨髓增殖性肿瘤(MPN)细胞。在MPN患者样本及小鼠模型中,Pevonedistat优先抑制骨髓纤维化(MF)集落生长,减弱TNFα反应,并抑制炎症因子过度产生,单用或联合鲁索替尼可降低疾病负荷、改善生存。研究为MF治疗中抑制NFκB信号提供了依据,并已启动Pevonedistat联合鲁索替尼的1期临床试验。
要点
- Pevonedistat抑制NFκB通路,靶向MPN恶性细胞,与鲁索替尼作用不冗余。
- Pevonedistat优先抑制MF集落生长,并减弱MF和sAML患者CD34+细胞的TNFα反应。
- Pevonedistat单用或联合鲁索替尼在MPN小鼠模型中降低疾病负荷并改善生存。
核心结论
- Pevonedistat通过抑制NFκB通路靶向MPN恶性细胞,在体外和体内均显示疗效,为MF治疗中抑制NFκB信号提供依据。
研究设计与样本
- 研究使用MPN患者样本以及MPN和患者来源异种移植小鼠模型,进行集落形成实验和质谱流式分析。
主要发现
- 集落形成实验显示Pevonedistat优先抑制MF集落生长而非正常集落形成。
- 质谱流式显示Pevonedistat减弱MF和sAML患者CD34+细胞的经典TNFα反应。
- Pevonedistat比鲁索替尼更有效地抑制炎症细胞因子过度产生。
- MPN小鼠模型中,Pevonedistat单用或联合鲁索替尼降低疾病负荷并改善生存。
临床怎么用
- Pevonedistat可能作为MF的靶向治疗药物,尤其针对NFκB通路过度激活且对JAK2抑制不敏感的患者。
- 基于这些发现,已启动Pevonedistat联合鲁索替尼的1期临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone persists and remains susceptible to disease transformation. These observations suggest that targeting alternative dysregulated signaling pathways may provide therapeutic benefit. Previous studies identified NFκB pathway hyperactivation in myelofibrosis (MF) and secondary acute myeloid leukemia (sAML) that was insensitive to JAK2 inhibition. Here, we provide evidence that NFκB pathway inhibition via pevonedistat targets malignant cells in MPN patient samples as well as in MPN and patient-derived xenograft mouse models that are nonredundant with ruxolitinib. Colony forming assays revealed preferential inhibition of MF colony growth compared with normal colony formation. In mass cytometry studies, pevonedistat blunted canonical TNFα responses in MF and sAML patient CD34+ cells. Pevonedistat also inhibited hyperproduction of inflammatory cytokines more effectively than ruxolitinib. Upon pevonedistat treatment alone or in combination with ruxolitinib, MPN mouse models exhibited reduced disease burden and improved survival. These studies demonstrating efficacy of pevonedistat in MPN cells in vitro as well as in vivo provide a rationale for therapeutic inhibition of NFκB signaling for MF treatment. Based on these findings, a Phase 1 clinical trial combining pevonedistat with ruxolitinib has been initiated.
引用
- Kong T, Laranjeira ABA, Collins TB, et al. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition. Blood Adv. 2022. PMID: 34644371. doi:10.1182/bloodadvances.2020002804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。